BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11807794)

  • 1. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
    Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
    Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
    Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
    Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
    Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
    J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
    Musselli C; Livingston PO; Ragupathi G
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
    Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
    Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
    Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
    Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
    Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
    Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
    Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
    J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
    Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
    Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
    Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
    Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.